NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Biotechnology

Healthcare
$19.74 +0.39%

+$0.12 today

Market cap
$2.37B
Beta
0.08
P/E (TTM)
-17.2
EPS (TTM)
-$1.76
52W Low $17.63High $42.21

Volume 1.80M

Average 1.21M

NAMS Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

NewAmsterdam Pharma Company N.V.NASDAQ: NAMS

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin dips below year-ago levels

Q2 FY2026 selling, general & admin of $26.89M fell 1.4% year over year, behind the +6.5% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 14.7% from the prior quarter. Over 3 fiscal years it compounded at +76.0% a year.

Context

  • Selling, general & admin amounted to 472.4% of revenue in FY2025, up 317.7 pp from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 10 analysts of $81.04M (-23.8%) for the fiscal year ending Dec 2026, a slowdown from the +50.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$26.89M+14.7% QoQ
Last fiscal yearDec 2025
$106.3M+50.9% YoY
LTMJun 2026
$102.22M+6.5% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.4%-27.1%-25.8 pp
1 year+50.9%-23.8%-74.7 pp
3-year CAGR+76.0%+77.3%+1.3 pp
5-year CAGR+83.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
106.3M USD
Year-over-year change
+50.9%
4-year CAGR
+108.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How NAMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +6.5% is the 7th highest of 9, against a peer median of +17.5%.
  • Selling, general & admin amounts to 1435.5% of revenue for NAMS, versus a peer median of 100.8%.
NAMS Competitors
Selling, General & Admin for NAMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$1.01B USD+64.1%+156.7%78.4%
DNLIDenali Therapeutics Inc.LTM Jun 2026$139.03M USD+19.2%+2.4%3857.6%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$102.22M USD+6.5%+76.0%1435.5%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$74.79M USD+15.8%-20.9%—
VKTXViking Therapeutics, Inc.LTM Jun 2026$50.71M USD-11.8%+44.2%—
SEPNSepterna, Inc.LTM Sep 2026$36.57M USD+38.0%—38.0%
BIOABioAge Labs, Inc.LTM Mar 2026$28.7M USD+27.8%+43.3%278.2%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$18.46M USD-7.7%+13.7%—
ATHEAlterity Therapeutics LimitedFY2025A$5.48M AUD+15.1%-0.2%100.8%
Peer median (excluding NAMS) —+17.5%+13.7%100.8%

Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0102.69M14.09M45.56M22.5M
Cost of Revenue000059K
Gross Profit0102.69M14.09M45.56M22.44M
Gross Margin—100.0%100.0%100.0%99.7%
Research & Development28.97M86.74M159.42M151.41M141.83M
Selling, General & Admin5.68M19.51M37.63M70.45M106.3M
Operating Expenses34.98M106.25M197.06M221.85M248.13M
Depreciation & Amortization5K9K49K113K220K
EBITDA(41.37M)(22.34M)(176.86M)(241.49M)(242.33M)
EBITDA Margin—-21.8%-1255.2%-530.0%-1076.9%
Operating Income(34.98M)(3.56M)(182.97M)(176.29M)(225.68M)
Operating Margin—-3.5%-1298.6%-386.9%-1002.9%
Interest Income0010.22M16.88M27.59M
Interest Expense411K287K6.8M00
Other Income / Expenses(6.81M)(19.08M)6.06M(65.31M)21.86M
Income Before Tax(41.79M)(22.63M)(176.91M)(241.6M)(203.82M)
Pre-Tax Margin—-22.0%-1255.6%-530.3%-905.7%
Income Tax Expense0027K(1K)0
Net Income(41.79M)(22.63M)(176.94M)(241.6M)(203.82M)
Net Margin—-22.0%-1255.8%-530.3%-905.7%
EPS (Basic)(3.34)(1.19)(2.15)(2.56)(1.75)
EPS (Diluted)(3.34)(1.19)(2.15)(2.56)(1.75)
Weighted Avg Shares17.75M18.97M82.16M94.36M114.4M
Weighted Avg Shares (Diluted)17.75M18.97M82.16M94.36M114.4M

NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Intrinsic Alpha fair value

Locked

Current Price

$19.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.